New Concepts of Personalized Therapy in Salivary Gland Carcinomas

Dear Colleagues,

Salivary gland cancer is a rare cancer accounting for less than 5% of all head and neck cancers. It also consists of cancers with diverse pathophysiology, which presents challenges to the field. However, recent progress in genomics and precision oncology has been transformative; now, we have several extremely promising biomarker-driven therapies based on robust preclinical and early clinical studies. As an example, Trk inhibitors for NTRK fusion-positive secretory carcinoma of the salivary gland have been approved and incorporated into standard care. Furthermore, androgen receptors and HER2-targeted therapy have been extensively investigated for salivary duct carcinomas in a few active studies. There are also exciting clinical developments in adenoid cystic carcinomas and cell-based immunotherapy. In this Special Issue, we are inviting the submission of papers focused on any aspect of evolving therapeutic methods for salivary gland cancers driven by advances in genomics, proteomics, informatics, and clinical care.

Dr. Hyunseok Kang
Dr. Jameel Muzaffar
Guest Editors

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Cancers is an international peer-reviewed open access semimonthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2900 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

• salivary gland cancer
• adenoid cystic carcinoma
• mucoepidermoid carcinoma
• salivary duct carcinoma
• secretory carcinoma
• precision oncology
• androgen receptor
• HER2
• Myb